Evidence map›Paper›PMID 33839923›Full record

Trial reportHeart and vessels2021

Association between anemia and mortality in patients with acute coronary syndrome treated with percutaneous coronary intervention and contemporary lipid-lowering therapy.

Masataka Ogiso, Junichi Yamaguchi, Hisao Otsuki, Hiroyuki Arashi, Haruki Sekiguchi, Hiroshi Ogawa, Nobuhisa Hagiwara

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Heart and vessels, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masataka OgisoDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.
Junichi YamaguchiDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan. j.yamaguchi0110@gmail.com.ORCID http://orcid.org/0000-0003-0967-0978
Hisao OtsukiDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.
Hiroyuki ArashiDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.
Haruki SekiguchiDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.
Hiroshi OgawaDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.
Nobuhisa HagiwaraDepartment of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1, Kawada-Cho, Shinjuku, Tokyo, 162-8666, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite a clear correlation between anemia and mortality in patients with the acute coronary syndrome (ACS), anemia as a mortality predictor in patients with ACS-receiving early invasive strategy and contemporary lipid-lowering therapy has not been examined. Therefore, we aimed to evaluate the association between anemia and mortality in ACS patients treated with acute revascularization and contemporary lipid-lowering treatment. This was a post-hoc study of the Heart Institute of Japan-Proper level of Lipid-Lowering with Pitavastatin and Ezetimibe in acute coronary syndrome study, in which ACS patients with dyslipidemia were randomized to receive either pitavastatin and ezetimibe or pitavastatin monotherapy. The success rate of primary percutaneous coronary intervention (PCI) was 95.2%. Eligible patients were divided into two groups: patients with anemia (anemia group) or without anemia (non-anemia group). Anemia was defined using the World Health Organization definition hemoglobin < 12 g/dL for women and < 13 g/dL for men. We compared the mortality between the two groups using propensity scores derived from 17 baseline variables. We identified 1721 eligible patients, including 420 (24.4%) in the anemia group and 1301 (75.6%) in the non-anemia group. One-to-one propensity score-matching created 381 pairs. Both unmatched and matched analyses found significantly high mortality in the anemia group compared to the non-anemia group (unmatched 12.3% vs. 3.8%, log-rank p < 0.01; matched 11.5% vs. 6.3%, log-rank p = 0.01). In ACS patients treated with an early invasive strategy era with a high PCI success rate and concurrent contemporary lipid-lowering management, all-cause mortality was still significantly higher in anemic patients than in non-anemic patients.Trial registration: Clinical trial registration URL: http://www.umin.ac.jp/ctr . Unique identifier: UMIN00000274.

Indexed as

Acute Coronary SyndromeAnemiaDyslipidemiasPercutaneous Coronary InterventionEzetimibeFemaleHumansMaleTreatment OutcomeEzetimibeAcute coronary syndromeAnemiaLipid-lowering therapyMortality

Identifiers

PMID33839923
OpenAlexW3156208011

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.